Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry.
A method for determination of a gamma-secretase inhibitor, cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid (A), in human plasma and cerebrospinal fluid (CSF) has been developed to support the clinical investigation of compound A for its potential treatment of Alzheimer's disease. The method is based on HPLC with atmospheric pressure chemical ionization tandem mass spectrometric detection (APCI-MS/MS) in the negative ionization mode using a heated nebulizer interface. The addition of phosphoric acid at the ratio of 10-30microL per milliliter of human plasma or CSF was required during clinical sample collection to stabilize an acylglucuronide metabolite (C), which was potentially present in human plasma and CSF. Tween 20 (10% solution) was added at the ratio of 20microL per milliliter of CSF during CSF sample collection to prevent the loss of compound A during the storage of clinical samples. The compound A and its analog internal standard (B) in treated plasma or CSF were isolated from human plasma or CSF using solid phase extraction (SPE) in the 96 well format. The isolated analyte and internal standard were chromatographed on a Phenomenex Synergi Polar RP analytical column (50mmx3.0mm, 4microm), using a mobile phase consisting of 60/40 (v/v, %) acetonitrile/water at a flow-rate of 0.5mL/min. Tandem mass spectrometric detection was performed using a Sciex API 3000 tandem mass spectrometer operated in the multiple reaction monitoring (MRM) mode using precursor to product ion transitions of 441-->175 for A and 469-->175 for B, respectively. The assays were validated over the concentration range of 0.5-200ng/mL for human plasma and CSF. Replicate analyses (n=5) of spiked standards for both assays yielded a linear response with coefficients of variation less than 7% and accuracy within 5% of the nominal concentrations. In addition, the assays were automated to improve sample throughput by utilizing a Packard Multi PROBEII automated liquid handling system and a Tom-Tec Quadra 96 system. Numerous clinical studies have been supported using these assays.
Matthews
Catherine Z
CZ
Department of Drug Metabolism, Sumneytown Pike, West Point, PA 19486, USA. catherine_matthews@merck.com
Woolf
Eric J
EJ
D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D001322:Autoanalysis; D002851:Chromatography, High Pressure Liquid; D003510:Cyclohexanes / Q000032:analysis* / Q000097:blood; D004791:Enzyme Inhibitors / Q000032:analysis* / Q000097:blood / Q000134:cerebrospinal fluid; D005615:Freezing; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D007202:Indicators and Reagents; D011422:Propionates / Q000032:analysis* / Q000097:blood; D011786:Quality Control; D013048:Specimen Handling; D053719:Tandem Mass Spectrometry
D003510:Cyclohexanes; D004791:Enzyme Inhibitors; D020719:Glucuronides; D007202:Indicators and Reagents; D011422:Propionates; C528336:cis-3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; D053829:Amyloid Precursor Protein Secretases